Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry

Author:

Geurts Sandra M. E.ORCID,Ibragimova Khava I. E.,Ding Nan,Meegdes Marissa,Erdkamp Frans,Heijns Joan B.,Tol Jolien,Vriens Birgit E. P. J.,Dercksen Marcus W.,Aaldering Kirsten N. A.,Pepels Manon J. A. E.,van de Winkel Linda,Peters Natascha A. J. B.,van de Wouw Agnes J.,Maaskant Sabrina A. J. G.,Teeuwen-Dedroog Nathalie J. A.,van Nijnatten Thiemo J. A.,de Boer Maaike,Tjan-Heijnen Vivianne C. G.

Abstract

Abstract Purpose The aim was to determine whether the real-world first-line progression-free survival (PFS) of patients diagnosed with de novo human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer (ABC) has improved since the introduction of pertuzumab in 2013. In addition to PFS, we aimed to determine differences in overall survival (OS) and the use of systemic and locoregional therapies. Methods Included were patients systemically treated for de novo HER2+ ABC in ten hospitals in 2008–2017 from the SONABRE Registry (NCT-03577197). First-line PFS and OS in 2013–2017 versus 2008–2012 was determined using Kaplan–Meier analyses and multivariable Cox proportional hazards modelling. First-given systemic therapy and the use of locoregional therapy within the first year following diagnosis were determined per period of diagnosis. Results Median and five-year PFS were 26.6 months and 24% in 2013–2017 (n = 85) versus 14.5 months and 10% in 2008–2012 (n = 81) (adjusted HR = 0.65, 95%CI:0.45–0.94). Median and five-year OS were 61.2 months and 51% in 2013–2017 versus 26.1 months and 28% in 2008–2012 (adjusted HR = 0.55, 95%CI:0.37–0.81). Of patients diagnosed in 2013–2017 versus 2008–2012, 84% versus 60% received HER2-targeted therapy and 59% versus 0% pertuzumab-based therapy as first-given therapy. Respectively, 27% and 23% of patients underwent locoregional breast surgery, and 6% and 7% surgery of a metastatic site during the first year following diagnosis. Conclusion The prognosis of patients with de novo HER2 + ABC has improved considerably. Since 2013 one in four patients were alive and free from progression on first-given therapy for at least five years.

Funder

Netherlands Organization for Health Research and Development

Novartis

Roche

Pfizer

Eli Lilly and Company

Gilead Sciences

AstraZeneca

Publisher

Springer Science and Business Media LLC

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3